cancer

Latecomer Sanofi looks to catch next wave of cancer therapies
Latecomer Sanofi looks to catch next wave of cancer therapies
Reuters
Sanofi
cancer
immuno-oncology
oncology
Flag link:
Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge
Finding Cancer Patients Is the Pharma Industry’s Unlikely Challenge
Bloomberg
patients
cancer
Bayer
Roche
diagnostics
Flag link:
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Is ASCO Sending Mixed Messages On Cancer Drug Value?
Forbes
ASCO
cancer
oncology
value
drug pricing
Flag link:
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
Reuters
biotech
IPOs
cancer
Nant
Patrick Soon-Shiong
Flag link:
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
A serious new hurdle for CRISPR: Edited cells might cause cancer, find two studies
Stat
CRISPR
gene editing
cancer
Flag link:
Scientists set out to build an ultra-fast camera to capture effect of new cancer drug tech
Scientists set out to build an ultra-fast camera to capture effect of new cancer drug tech
Endpoints
UK
biotech
cancer
devices
Flag link:
A new cancer care dilemma: Patients want immunotherapy even when evidence is lacking
A new cancer care dilemma: Patients want immunotherapy even when evidence is lacking
Stat
patients
cancer
immunotherapy
Flag link:
Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer
Biotech Firm Grail Takes The First Steps In Its Quest For A Blood Test For Cancer
Forbes
Grail
cancer
oncology
diagnostics
Flag link:
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results
Xconomy
clinical trials
Roche
Genentech
Genmab
JNJ
cancer
Tecentriq
Darzalex
Flag link:
MIT researchers send drug-ferrying nanoparticles across the blood-brain barrier
MIT researchers send drug-ferrying nanoparticles across the blood-brain barrier
Drug Delivery Business News
MIT
blood-brain barrier
drug delivery
cancer
Flag link:
Beating Cancer With AI Or Achieving Brexit On Time: A Leadership Challenge For Theresa May
Beating Cancer With AI Or Achieving Brexit On Time: A Leadership Challenge For Theresa May
Forbes
artificial intelligence
cancer
Theresa May
UK
Brexit
Flag link:
GRAIL Raises $300 Million in Series C to Pursue Early Cancer Detection Mission
GRAIL Raises $300 Million in Series C to Pursue Early Cancer Detection Mission
CP Wire
Grail
cancer
diagnostics
Flag link:
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
FDA Clears IND for CytomX's CX-2029, a CD71-Directed Probody Therapeutic
CP Wire
CytomX
AbbVie
CX-2029
cancer
Flag link:
Precision Cancer Company Accent Therapeutics Launches with $40 Million Series A Round
Precision Cancer Company Accent Therapeutics Launches with $40 Million Series A Round
CP Wire
Accent Therapeutics
RMPs
cancer
precision medicine
Flag link:
With Training, Startups Like Paige.AI Could Soon Diagnose Cancer
With Training, Startups Like Paige.AI Could Soon Diagnose Cancer
Xconomy
Paige.AI
artificial intelligence
cancer
diagnostics
Flag link:
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
Exelixis and Invenra Partner to Develop Novel Biologics for Cancer Treatment
CP Wire
Exelixis
Invenra
cancer
Merck
drug development
Flag link:
Is Biopharma Investing Too Much In Cancer R&D?
Is Biopharma Investing Too Much In Cancer R&D?
Forbes
R&D
cancer
Flag link:
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies
Endpoints
Novartis
cancer
Pharma CEOs
Vas Narasimhan
Flag link:
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
San Francisco Gate, CA
lung cancer
cancer
Merck
Roche
Bristol-Myers Squibb
AACR
non-small cell lung cancer
Flag link:
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors
CP Wire
Nektar Therapeutics
NKTR-214
NKTR-262
cancer
solid tumors
Flag link:

Pages